Johnson & Johnson MedTech (NYSE:JNJ) today announced 12-month pilot data from a study of its investigational Omnypulse ...
Johnson & Johnson today announced 12-month pilot-phase data from the OMNY-AF study, evaluating the investigational OMNYPULSE Platform for the treatment of symptomatic paroxysmal atrial fibrillation ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results